Study finds up to 94% of papillary thyroid cancers in the past three decades were overdiagnosed, with stable mortality rates, despite soaring detection rates.

The evolving story of GLP-1 receptor agonists in oncology has yet another new chapter.Several studies presented at San Antonio Breast Cancer Symposium suggested the medications may help extend ...

The data presented by the ministry of health and family welfare revealed that the incidence of cancer cases had continuously been rising in the state; Haryana reported 18,387 cancer deaths, while ...

Fewer Singapore breast cancer deaths are due to earlier diagnoses and improved treatment, despite a rise in cases. Read more at straitstimes.com. Read more at straitstimes.com.

Post-diagnosis weight gain over ~1.5 years is consistently associated with increased breast cancer–specific and all-cause mortality across meta-analyses. How GLP-1 weight-loss drugs fit after breast ...

Historic redlining, a U.S. policy outlawed nearly 6 decades ago for segregating neighborhoods based on their racial makeup, still negatively impacts survival from breast cancer, according to results ...

FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions OS ...

The UK's first comprehensive evaluation of the use of Artificial Intelligence (AI) in breast cancer screening found that it can increase breast cancer detection by 10.4% and has the potential to ...

The University of Aberdeen said using AI as a second scan reader – substituting one human reader, and as an extra reader serving as a safeguard – resulted in the best combination of workload savings ...

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...

A systemwide collaborative integrates palliative care, EHR-based patient flagging, and cross-disciplinary support to address the psychosocial and clinical risks that often derail cancer treatment.

The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...